Citation Impact
Citing Papers
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Cytokines in CAR T Cell–Associated Neurotoxicity
2020
Engineered T Cell Therapy for Cancer in the Clinic
2019
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells
2020
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 StandoutNobel
Genetically engineered T cells for cancer immunotherapy
2019
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
2018
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease
2015
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
2018
Works of Mrinalini Bilgi being referenced
Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
2017
Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease
2013